Ionis EVP buys stock via employee plan

Ionis Pharmaceuticals executive Frank Bennett, EVP and Chief Scientific Officer, reported a small personal share purchase through the company’s employee stock purchase plan.

Accepted by SEC EDGAR 03/03/2026 - 05:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Frank Bennett, EVP and Chief Scientific Officer, reported a small personal share purchase through the company’s employee stock purchase plan. On February 27, 2026, he acquired 261 shares of Ionis common stock at $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan.

Following this transaction, Bennett directly owns 100,554 common shares. According to the filing, these newly purchased shares are subject to a holding period and may not be sold until August 27, 2026, which temporarily restricts his ability to dispose of this specific block of stock.

Insider Trade Summary

Other: 261 shares

Other 1 txn

Insider BENNETT C FRANK

Role EVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Other	Common Stock	261	$48.8665	$13K

Holdings After Transaction: Common Stock — 100,554 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis Pharmaceuticals (IONS) report for Frank Bennett?

Ionis Pharmaceuticals reported that EVP and Chief Scientific Officer Frank Bennett purchased 261 shares of common stock. The shares were bought through the company’s Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026, and are subject to a post-purchase holding period.

How many Ionis (IONS) shares did Frank Bennett buy and at what price?

Frank Bennett purchased 261 shares of Ionis common stock at a price of $48.8665 per share. The acquisition occurred on February 27, 2026, under the company’s employee stock purchase plan, reflecting a routine participation in a benefit program for eligible employees.

What is Frank Bennett’s total Ionis (IONS) share ownership after this Form 4?

After the reported purchase, Frank Bennett directly owns 100,554 shares of Ionis Pharmaceuticals common stock. This total reflects his holdings immediately following the 261-share acquisition under the employee stock purchase plan disclosed in the Form 4 filing.

Were Frank Bennett’s newly purchased Ionis (IONS) shares immediately saleable?

No. The 261 shares purchased by Frank Bennett under the Ionis employee stock purchase plan may not be sold until August 27, 2026. This holding restriction applies specifically to this transaction and reflects plan terms limiting near-term resale of acquired shares.

Under what plan did Frank Bennett acquire Ionis (IONS) shares in this transaction?

Frank Bennett acquired his shares under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan. The Form 4 footnote specifies that the 261 shares were purchased via this plan on February 27, 2026, with a required holding period before sale.

What transaction code was used in Frank Bennett’s Ionis (IONS) Form 4 filing?

The transaction was reported with code “J,” which indicates another type of acquisition or disposition. A footnote clarifies that this specific event was a purchase of 261 common shares under the employee stock purchase plan, rather than an open-market buy or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENNETT C FRANK

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		J		261(1)	A	$48.8665	100,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.